Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra, is now available. Apidra SoloSTAR makes administration of insulin more ...

The FDA has approved Apidra (insulin glulisine [rDNA origin] injection, from sanofi-aventis) for the treatment of type 1 diabetes in children ≥4 years old. This approval was based on a 26-week, ...

BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

To earn CME related to this news article, click here. January 6, 2009 — The US Food and Drug Administration (FDA) has approved revisions to the safety labeling, adding adverse event information for ...

European Commission approves Apidra for diabetes Apidra has a rapid onset and short duration of action which allows covering the postprandial hyperglycaemic peaks. It should normally be used in ...

BRIDGEWATER, N.J. The Food and Drug Administration has approved Apidra, a drug for improving glycemic control in diabetic children aged 4 and older, manufacturer Sanofi-Aventis said Wednesday. The FDA ...

April 22, 2004 — The U.S. Food and Drug Administration (FDA) has approved insulin glulisine injection for diabetes, triamcinolone acetonide nasal aerosol for allergic rhinitis, abacavir sulfate for ...

WASHINGTON The Food and Drug Administration approved Sanofi-Aventis drug Apidra on Friday, FDA records show. The injectable drug, known generically as insulin glulusine (rDNA origin), is approved for ...

DA Approves New Route of Administration for Sanofi-Aventis's Rapid-Acting Apidra BRIDGEWATER, N.J., June 15 -- Sanofi-aventis announced today that following a review of a supplemental New Drug ...

PARIS, Feb 26 (Reuters) - Sanofi-Aventis has won U.S. approval to market its Apidra Solostar injection pen which contains insulin to treat diabetes, the world's third-biggest drugmaker said on ...

Approval of APIDRA® gives a shot-in-the-arm to treatment of diabetes, especially in countries like the UAE where diabetes prevalence is among the highest in the world Sanofi-aventis announced ...

- First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin "Comparison of 3 intensified ...